Comparing Check-Cap (CHEK) and Its Peers
Check-Cap (NASDAQ: CHEK) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Check-Cap to similar companies based on the strength of its risk, earnings, analyst recommendations, profitability, institutional ownership, dividends and valuation.
Institutional & Insider Ownership
19.3% of Check-Cap shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Check-Cap and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Check-Cap has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500. Comparatively, Check-Cap’s rivals have a beta of 0.85, suggesting that their average share price is 15% less volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Check-Cap and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Check-Cap currently has a consensus price target of $6.00, suggesting a potential upside of 209.28%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 16.32%. Given Check-Cap’s stronger consensus rating and higher possible upside, research analysts plainly believe Check-Cap is more favorable than its rivals.
Valuation & Earnings
This table compares Check-Cap and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Check-Cap Competitors||$2.57 billion||$977.16 million||0.71|
Check-Cap’s rivals have higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Check-Cap rivals beat Check-Cap on 8 of the 12 factors compared.
Check-Cap Company Profile
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.
Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.